Updated on November 14, 2017
New Company: Brickell Biotech
Brickell Biotech, a dermatology-focused pharmaceutical company, is developing a therapy which should prove to be of interest to the online hair community.
The company is based in Boulder, CO and has a variety of clinical programs underway in the area of dermatology. One such program is an oral CRTH2 antagonist for hair loss. A “CRTH2 antagonist” is another way of saying a “‘Prostaglandin D2 receptor 2 antagonist”, which should sound familiar to you. The CRTH2/PD2 mechanism of action has been quite the rave over the past few years in the hair-growth research world, and apparently Brickell has a novel molecule which acts on it.
The molecule is known as BBI-5000 and is also being developed by Brickell to treat atopic dermatitis. According to Brickell, BBI-5000 has completed the phase 1 stage of trials and its next stages of development are under consideration. New oral medications that improve hair growth and prevent loss will certainly be a commodity to go with all of the topical and injectable treatments on the horizon. For more, check the Brickell Biotech website.
It is appreciated that you cite this article if you share this news 🙂